Long acting
human insulin are projected to grow with higher pace during the forecasted period in the product type segment, owing to their higher efficiency and ability to offer consistent insulin delivery throughout the day, lasting 24 hours.
Kitaoka et al., "Switching from premixed
human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life," Internal Medicine, vol.
Hui et al6 studied the effects of insulin lispro Mix50 [50% short-acting lispro/50% intermediate-acting lispro protamine] and
human insulin 30/70 on glycaemic control during Ramadan.
The longitudinal relationship of time-varying BMI with time-varying glycaemic control, adjusted for exogenous
human insulin replacement and other covariates, was examined by multilevel mixed-effects linear regression analysis, which accounted for the correlated repeated measurements of covariates within subjects.
Then, the objective of this work was to investigate the effects of
human insulin and 20E on some indicators of reproduction (vitellogenins, vitellins, ovarian ecdysteroids and reproductive potential) due to the role of these hormones on this process (Riehle and Brown, 1999; Maniere et al., 2004; De Loof, 2008; Belles and Piulachs, 2015).
Human insulin drugs segment is expected to account for the larger share of the global
human insulin market in 2015, followed by insulin delivery devices.
Inhaled rapid-acting
human insulin has also been investigated as add-on therapy to basal insulin providing similar glycemic control compared to twice-daily premixed biaspart insulin.
Most systematic reviews of analogue insulin find them to be of marginal advantage compared with
human insulin. The long-acting analogues, in particular, which are those mainly used in people with type 2 diabetes, offer no significant benefits, unless patients have been having symptomatic hypoglycaemia, particularly at night, a rare situation.
Mature
human insulin (molecular weight, 5808 Da) consists of 2 peptide chains (A and B) linked by 2 disulfide bonds.
It is an analogue of
human insulin that is produced in a non-pathogenic strain of Escherichia coli.
A Finnish study of 69 pregnant women treated with either lispro or conventional
human insulin, for instance, showed no significant differences in retinopathy progression (Diabetes Care 2003;26:1193-8).
The survey done on May 11 in Abu Dhabi showed that soluble
human insulin 100 IU/ml injection, produced by local manufacturer Julphar was cheaper by $4.63 (Dh17) than the most expensive brand available in the market.